Cochrane Review Group

Breast Cancer

49 systematic reviews in Breast Cancer ask 487 questions. 9% have no studies to answer them, 22.2% rest on very low certainty evidence and 39.7% reach moderate or high certainty.

Reviews

Questions

487

current versions

No studies

Moderate or high

39.7%

No studies 44 · 9%Ungraded 14 · 2.9%Very low 108 · 22.2%Low 128 · 26.3%Moderate 107 · 22%High 86 · 17.7%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Breast Cancer

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Shared decision‐making (all components) vs control Satisfaction with the decision‐making process · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies
Some components of shared decision‐making, including clarification of values and preferences, vs control Adherence to the chosen option · women aged 38 to 71 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies
Some components of shared decision‐making, including clarification of values and preferences, vs control Choice of an option aligned with each woman’s values and preferences · women aged 38 to 71 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies
Some components of shared decision‐making, including clarification of values and preferences, vs control Woman's involvement · women aged 38 to 71 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies
Studies focused only on enhanced communication, without clarification of values and preferences, vs control Satisfaction with the decision‐making process · women aged 40 to 75 years old at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies
Studies focused only on enhanced communication, without clarification of values and preferences, vs control Adherence to the chosen option · women aged 40 to 75 years old at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies
Studies focused only on enhanced communication, without clarification of values and preferences, vs control Choice of an option aligned with each woman’s values and preferences · women aged 40 to 75 years old at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies
Shared decision‐making (all components) vs control Confidence in the decision made · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies
Studies focused only on enhanced communication, without clarification of values and preferences, vs control Woman's involvement · women aged 40 to 75 years old at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies
Shared decision‐making (all components) vs control Knowledge of all the options · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	RR 1.18 [0.61, 2.28]	1 study · 133 participants	Very low
Shared decision‐making (all components) vs control Adherence to the chosen option · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies
Shared decision‐making (all components) vs control Choice of an option aligned with each woman’s values and preferences · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane	no estimate extracted	NR	No studies

Reviews 49

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer

Zaheed, M, Wilcken, N, et al. · Cochrane Database of Systematic Reviews · 2019

Breast Cancer

Thinnest evidence

Reviews 49

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer

Breast surgery for metastatic breast cancer

Physical activity for women with breast cancer after adjuvant therapy

Platinum‐containing regimens for metastatic breast cancer

Bisphosphonates and other bone agents for breast cancer

Axillary treatment for operable primary breast cancer

Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women diagnosed with breast cancer

Fulvestrant for hormone‐sensitive metastatic breast cancer

Home‐based multidimensional survivorship programmes for breast cancer survivors

Online support groups for women with breast cancer

Tumour bed boost radiotherapy for women after breast‐conserving surgery

Follow‐up strategies for women treated for early breast cancer

High‐dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer

Hypofractionated radiation therapy for early breast cancer

Exercise for women receiving adjuvant therapy for breast cancer

Nipple‐ and areola‐sparing mastectomy for the treatment of breast cancer

Different types of implants for reconstructive breast surgery

Conservative interventions for preventing clinically detectable upper‐limb lymphoedema in patients who are at risk of developing lymphoedema after breast cancer therapy

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)

Trastuzumab‐containing regimens for metastatic breast cancer

Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary surgery

Trastuzumab containing regimens for early breast cancer

Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile neutropenia in breast cancer patients

Non‐hormonal interventions for hot flushes in women with a history of breast cancer